A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma

  • Authors:
    • Michio Kimura
    • Eiseki Usami
    • Hitomi Teramachi
    • Tomoaki Yoshimura
  • View Affiliations

  • Published online on: January 16, 2020     https://doi.org/10.3892/mco.2020.1978
  • Pages: 284-289
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nivolumab and axitinib has recommended as a second‑line treatment in patients with metastatic renal cell carcinoma (mRCC) after tyrosine kinase inhibitor treatment. In this study, overall survival (OS), treatment continuation, and the cost of nivolumab and axitinib‑the second‑line treatment agents for mRCC‑were compared and examined. Herein, we retrospectively surveyed patients with pathologically confirmed mRCC, treated with nivolumab (n=9) or axitinib (n=16) at Ogaki Municipal Hospital (Ogaki, Japan) between January 2012 and May 2019. The treatment periods for the nivolumab‑ and axitinib‑administered groups were 5.4 (range: 1.4‑21.3) and 3.4 (range: 0.3-28.1) months, respectively (P=0.089). The postponement periods for the nivolumab‑ and axitinib‑administered groups were 7 (range: 0‑186) and 0 (range: 0‑262) days, respectively, and the difference was statistically significant (P=0.008). The median OS for patients treated with nivolumab and axitinib was 12.3 (range: 1.5‑25.5 months) and 9.2 (range: 2.2‑55.0 months) months, respectively (P=0.633). The one‑year cost estimates for axitinib and nivolumab in clinical practice were $60,694.2 and $86,544.4, respectively (P=0.017). We found that despite frequent interruptions in nivolumab administration and a longer postpaonement period for the nivolumab‑administered group than for the axitinib‑administered group, both groups exhibit comparable treatment duration and OS.
View Figures
View References

Related Articles

Journal Cover

March 2020
Volume 12 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Kimura, M., Usami, E., Teramachi, H., & Yoshimura, T. (2020). A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma. Molecular and Clinical Oncology, 12, 284-289. https://doi.org/10.3892/mco.2020.1978
MLA
Kimura, M., Usami, E., Teramachi, H., Yoshimura, T."A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma". Molecular and Clinical Oncology 12.3 (2020): 284-289.
Chicago
Kimura, M., Usami, E., Teramachi, H., Yoshimura, T."A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma". Molecular and Clinical Oncology 12, no. 3 (2020): 284-289. https://doi.org/10.3892/mco.2020.1978